Session – Strategies to Ensure Strong and Efficient CMC Function at Startup Biotechs Gregg is the Vice President of Product Development at an Atlas Venture biotech startup company which is currently in stealth mode. As Vice President of Product Development at Cadent Therapeutics, he managed CMC Development, quality, intellectual property, clinical distribution, and other portfolio management functions. At Ataxion Therapeutics, he led the medicinal chemistry program and coordinated its fully-externalized drug discovery model. Gregg was one of the very first employees at H3 Biomedicine and headed its program on natural product-based splicing modulators. His industrial career began at Infinity Pharmaceuticals, and he received his Ph.D. in synthetic organic chemistry from Yale University.